The Medical Letter on Drugs and Therapeutics
Tenofovir Alafenamide (Vemlidy) for Hepatitis B
The full article is available to subscribers Subscriber Login   

The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir, to become available; several combination products containing TAF are approved for treatment of HIV-1 infection. Tenofovir disoproxil fumarate (TDF; Viread – Gilead), another tenofovir prodrug, has been used for many years for treatment of chronic HBV infection; a generic formulation of TDF is expected to become available in December 2017.

STANDARD TREATMENT — The goal of chronic HBV treatment is to reduce the risk of cirrhosis, hepatic failure, and hepatocellular carcinoma. Effective therapy can reduce the viral load and promote HBV e-antigen seroconversion (loss of HBeAg with development of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Tenofovir Alafenamide (Vemlidy) for Hepatitis B
Article code: 1511d
 Electronic, downloadable article - $25